Skip to content
    Real-World Studies

    Neoadjuvant Pembrolizumab Shows High Toxicity in Triple-Negative Breast Cancer

    Jude et alAsia-Pacific journal of clinical oncology

    Neoadjuvant Pembrolizumab Shows High Toxicity in Triple-Negative Breast Cancer
    In this multicenter retrospective study conducted across three tertiary hospitals in Melbourne, Australia, researchers evaluated real-world outcomes and toxicity associated with the KEYNOTE-522 neoadjuvant regimen of pembrolizumab combined with chemotherapy for triple-negative breast cancer (TNBC). Following the KEYNOTE-522 trial, neoadjuvant chemo-immunotherapy became the standard of care in Australia, where clinical trial data previously showed higher pathological complete response (pCR) at the cost of increased immune-related adverse events (irAEs). The cohort included 54 female patients (median age: 52 years; median follow-up: 26 months) who initiated treatment between December 2022 and August 2024, with follow-up extending to October 30, 2025. At diagnosis, 69% presented with nodal involvement, and 3 patients had a pre-existing history of autoimmune disease.
    Overall, 65% of patients developed at least one irAE. The most common toxicities were thyroid dysfunction (28%), adrenal dysfunction (20%), colitis (9%), and arthralgias (9%), with a median time to onset of 84 days (range: 22–505 days). Among those who developed an irAE, 43% required hospitalization, 9% required intensive care unit admission, and 51% had ongoing sequelae. The pCR rate across the entire cohort was 50%, and no difference in pCR was identified between patients who experienced an irAE and those who did not (p = 0.081). The authors concluded that real-world use of neoadjuvant pembrolizumab in TNBC showed a higher proportion of irAEs compared to the original KEYNOTE-522 trial, with a notable rate of hospitalizations that should help guide shared clinical decision-making.

    Key Takeaways

    • Among patients with triple-negative breast cancer receiving neoadjuvant pembrolizumab plus chemotherapy, 65% experienced at least one immune-related adverse event (irAE), of whom 43% required hospitalization, 9% needed intensive care, and 51% developed ongoing sequelae.
    • The overall pathological complete response (pCR) rate was 50%, with no difference observed between patients who experienced an irAE and those who did not (p = 0.081).
    • The most frequent irAEs were thyroid dysfunction (28%), adrenal dysfunction (20%), colitis (9%), and arthralgias (9%), with a median onset time of 84 days (range: 22–505 days).
    Read the original sourceAsia-Pacific journal of clinical oncology